Lanreotide

Definition

A synthetic cyclic octapeptide analogue of somatostatin. Lanreotide binds to somatostatin receptors (SSTR), specifically SSTR-2 and also to SSTR-5 with a lesser affinity. However, compare with octreotide, this agent is less potent in inhibiting the release of growth hormone from the pituitary gland. Furthermore, lanreotide has an acute effect on decreasing circulating total and free insulin-like growth factor 1 (IGF-I). This agent is usually given as a prolonged-release microparticle or Autogel formulation for the treatment of acromegaly and to relieve the symptoms of neuroendocrine tumors.

Also known as Angiopeptin, BIM-23014, DC 13116, Dermopeptin, Ipstyl, L-Threoninamide, 3-(2-naphthalenyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-, cyclic (2-7)-disulfide, LANREOTIDE, Nal-cyclo(cys-tyr-trp-lys-val-cys)-thr-NH2, Somatulina, Somatuline — per NCIT

Also identified as

• ATC H01CB03 per RXNORM
• NCIT NCIT:C1523 per NCIT
• SCTID 327379003 per RXNORM
• SCTID 395765000 per RXNORM
• UNII 0G3DE8943Y per RXNORM

Indications

Organ Effects

1 entry above is marked DERIVED: Atlas Médico inferred it by combining two sourced claims, and no source asserts this link directly. Treat it as a navigation aid, not as a clinical statement.